148 related articles for article (PubMed ID: 18347142)
1. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.
Mason CK; McFarlane S; Johnston PG; Crowe P; Erwin PJ; Domostoj MM; Campbell FC; Manaviazar S; Hale KJ; El-Tanani M
Mol Cancer Ther; 2008 Mar; 7(3):548-58. PubMed ID: 18347142
[TBL] [Abstract][Full Text] [Related]
2. Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.
El-Tanani MK; Jin D; Campbell FC; Johnston PG
Oncogene; 2010 Feb; 29(5):752-62. PubMed ID: 19901966
[TBL] [Abstract][Full Text] [Related]
3. [Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines].
Lin F; Li YY; Xia JT; Wen MJ; Lai YY; Cai WS; Wu ZF; Fan SF
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):422-5. PubMed ID: 19567019
[TBL] [Abstract][Full Text] [Related]
4. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Schulze EB; Hedley BD; Goodale D; Postenka CO; Al-Katib W; Tuck AB; Chambers AF; Allan AL
Breast Cancer Res Treat; 2008 Nov; 112(2):243-54. PubMed ID: 18097747
[TBL] [Abstract][Full Text] [Related]
5. Total synthesis of (+/-)-agelastatin A, a potent inhibitor of osteopontin-mediated neoplastic transformations.
Dickson DP; Wardrop DJ
Org Lett; 2009 Mar; 11(6):1341-4. PubMed ID: 19228041
[TBL] [Abstract][Full Text] [Related]
6. Role of osteopontin in cellular signaling and metastatic phenotype.
El-Tanani MK
Front Biosci; 2008 May; 13():4276-84. PubMed ID: 18508510
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Agelastatin Derivatives as Potent Modulators for Cancer Invasion and Metastasis.
Antropow AH; Xu K; Buchsbaum RJ; Movassaghi M
J Org Chem; 2017 Aug; 82(15):7720-7731. PubMed ID: 28696693
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells.
Gao C; Mi Z; Guo H; Kuo PC
Neoplasia; 2007 Sep; 9(9):699-706. PubMed ID: 17898865
[TBL] [Abstract][Full Text] [Related]
9. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin.
Kurisetty VV; Johnston PG; Johnston N; Erwin P; Crowe P; Fernig DG; Campbell FC; Anderson IP; Rudland PS; El-Tanani MK
Oncogene; 2008 Dec; 27(57):7139-49. PubMed ID: 18794800
[TBL] [Abstract][Full Text] [Related]
10. Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer.
Ravindranath A; Yuen HF; Chan KK; Grills C; Fennell DA; Lappin TR; El-Tanani M
Br J Cancer; 2011 Aug; 105(4):542-51. PubMed ID: 21772333
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
Yang L; Wei L; Zhao W; Wang X; Zheng G; Zheng M; Song X; Zuo W
Mol Med Rep; 2012 Feb; 5(2):373-6. PubMed ID: 22143930
[TBL] [Abstract][Full Text] [Related]
12. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
Liu H; Chen A; Guo F; Yuan L
Cancer Lett; 2010 Sep; 295(1):27-37. PubMed ID: 20207476
[TBL] [Abstract][Full Text] [Related]
13. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin as a target for cancer therapy.
Johnston NI; Gunasekharan VK; Ravindranath A; O'Connell C; Johnston PG; El-Tanani MK
Front Biosci; 2008 May; 13():4361-72. PubMed ID: 18508515
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis.
Sun BS; You J; Li Y; Zhang ZF; Wang CL
Chin Med J (Engl); 2013; 126(9):1683-8. PubMed ID: 23652051
[TBL] [Abstract][Full Text] [Related]
16. [Effect of short-hairpin RNA expression vector-mediated osteopontin RNA interference on proliferation and invasion of prostate cancer PC-3 cells].
Liu H; Chen AM; Guo FJ; Liao H; Hu WH; Xie J
Chin J Cancer; 2010 Jan; 29(1):43-51. PubMed ID: 20038310
[TBL] [Abstract][Full Text] [Related]
17. Identification of brefelamide as a novel inhibitor of osteopontin that suppresses invasion of A549 lung cancer cells.
Zhang J; Yamada O; Kida S; Matsushita Y; Murase S; Hattori T; Kubohara Y; Kikuchi H; Oshima Y
Oncol Rep; 2016 Oct; 36(4):2357-64. PubMed ID: 27498705
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
El-Tanani MK; Yuen HF; Shi Z; Platt-Higgins A; Buckley NE; Mullan PB; Harkin DP; Johnston PG; Rudland PS
Cancer Sci; 2010 Jun; 101(6):1354-60. PubMed ID: 20384635
[TBL] [Abstract][Full Text] [Related]
19. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
Gong M; Lu Z; Fang G; Bi J; Xue X
Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 suppresses osteopontin-mediated breast cancer.
El-Tanani MK; Campbell FC; Crowe P; Erwin P; Harkin DP; Pharoah P; Ponder B; Rudland PS
J Biol Chem; 2006 Sep; 281(36):26587-601. PubMed ID: 16807234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
